Francesco Bianchi Sells 1,800 Shares of LivaNova (NASDAQ:LIVN) Stock

Posted by Stanley Muller on May 29th, 2026

LivaNova PLC (NASDAQ:LIVN – Get Free Report) Director Francesco Bianchi sold 1,800 shares of the stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $75.75, for a total value of $136,350.00. Following the sale, the director directly owned 7,228 shares in the company, valued at $547,521. This represents a 19.94% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

LivaNova Trading Down 1.2%

Shares of NASDAQ:LIVN opened at $73.04 on Friday. The business’s 50 day simple moving average is $66.37 and its 200 day simple moving average is $64.21. The company has a market capitalization of $4.01 billion, a P/E ratio of 37.46 and a beta of 0.82. LivaNova PLC has a 1 year low of $41.01 and a 1 year high of $75.82. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.33 and a quick ratio of 1.11.

LivaNova (NASDAQ:LIVN – Get Free Report) last issued its earnings results on Wednesday, May 6th. The company reported $0.98 earnings per share for the quarter, beating analysts’ consensus estimates of $0.85 by $0.13. The firm had revenue of $362.26 million for the quarter, compared to the consensus estimate of $346.05 million. LivaNova had a return on equity of 16.48% and a net margin of 7.48%.The company’s revenue was up 14.3% compared to the same quarter last year. During the same quarter last year, the business posted $0.88 EPS. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. On average, research analysts anticipate that LivaNova PLC will post 3.72 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of LIVN. Hantz Financial Services Inc. lifted its holdings in LivaNova by 159.9% during the 4th quarter. Hantz Financial Services Inc. now owns 434 shares of the company’s stock worth $27,000 after buying an additional 267 shares during the period. State of Wyoming acquired a new stake in shares of LivaNova during the second quarter worth $31,000. EverSource Wealth Advisors LLC increased its position in shares of LivaNova by 998.4% during the second quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock worth $32,000 after buying an additional 639 shares during the period. Quarry LP acquired a new stake in shares of LivaNova during the third quarter worth $36,000. Finally, UMB Bank n.a. increased its position in shares of LivaNova by 63.0% during the third quarter. UMB Bank n.a. now owns 792 shares of the company’s stock worth $41,000 after buying an additional 306 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts recently commented on LIVN shares. Needham & Company LLC increased their price objective on shares of LivaNova from $64.00 to $81.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Stifel Nicolaus set a $80.00 price objective on shares of LivaNova in a research note on Wednesday, February 25th. Weiss Ratings raised shares of LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a research note on Thursday, May 7th. Barclays raised their price objective on LivaNova from $73.00 to $76.00 and gave the company an “equal weight” rating in a report on Thursday, May 7th. Finally, Robert W. Baird cut their price objective on LivaNova from $78.00 to $76.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Six investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, LivaNova presently has a consensus rating of “Moderate Buy” and a consensus target price of $79.38.

Get Our Latest Research Report on LivaNova

LivaNova Company Profile

(Get Free Report)

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.